13 years later, is it still considered a startup?

11:57 AM,
Jan. 18, 2014

Written by

Laura
Baverman

Its stock price ended the year up more than 400 percent. A Big Pharma giant became a partner, bolstering the company's image as an up-and-comer in biotechnology and bringing at least $400 million into the firm. And a handful of vaccines in the West Point, Pa., company's pipeline showed promise in treating cancer and fighting disease.

And yet - after 13 years of work - there's still no product on the market. And the vaccines, as revolutionary as they promise to be, have only just begun to be tested in patients. The stock price ...